A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. TPS653-TPS653
Author(s):  
Denise A. Yardley ◽  
Ahmad Awada ◽  
Javier Cortes ◽  
Howard A. Burris ◽  
Amy C. Peterson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Multicenter Trial ◽  
Advanced Breast ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Double Blind Placebo

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

2010 ◽  
Vol 30 (2) ◽  
pp. 681-687 ◽  
Author(s):  
Katalin Boér ◽  
István Láng ◽  
Antonio Llombart-Cussac ◽  
Inger Andreasson ◽  
Guillermo L. Vivanco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Breast ◽  
Line Treatment ◽  
Second Line ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Randomized Phase Ii

scholarly journals Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

2020 ◽  
Vol 21 (10) ◽  
pp. 1269-1282 ◽  
Author(s):  
Véronique Diéras ◽  
Hyo S Han ◽  
Bella Kaufman ◽  
Hans Wildiers ◽  
Michael Friedlander ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document